In 2017 MSZC filed suit on behalf of Errant Gene Therapeutics (EGT) in New York State Supreme Court against Sloan Kettering Institute for Cancer Research and Bluebird Bio for fraud, unfair competition, and breach of contract related to development of a potentially life‐saving gene therapy treatment for Thalassemia.
In November 2020 the parties were able to reach a settlement during trial.